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Although biofilms have been observed early in the
history of microbial research, their impact has only
recently been fully recognized. Biofilm infections,
which contribute to up to 80% of human microbial
infections, are associated with common human
disorders, such as diabetes mellitus and poor
dental hygiene, but also with medical implants.
The associated chronic infections such as wound
infections, dental caries and periodontitis signifi-
cantly enhance morbidity, affect quality of life and
can aid development of follow-up diseases such as
cancer. Biofilm infections remain challenging to
treat and antibiotic monotherapy is often insuffi-
cient, although some rediscovered traditional com-
pounds have shown surprising efficiency.
Innovative anti-biofilm strategies include applica-
tion of anti-biofilm small molecules, intrinsic or
external stimulation of production of reactive
molecules, utilization of materials with antimicro-
bial properties and dispersion of biofilms by diges-
tion of the extracellular matrix, also in combination
with physical biofilm breakdown. Although basic
principles of biofilm formation have been deci-
phered, the molecular understanding of the forma-
tion and structural organization of various types of
biofilms has just begun to emerge. Basic studies of
biofilm physiology have also resulted in an unex-
pected discovery of cyclic dinucleotide second
messengers that are involved in interkingdom
crosstalk via specific mammalian receptors. These
findings even open up new venues for exploring
novel anti-biofilm strategies.
Keywords: antimicrobial strategies, biofilm forma-
tion, cyclic di-nucleotide second messengers,
extracellular matrix, underlying diseases.
Introduction
The 60th Nobel Conference on Biofilm formation –
its clinical impact and potential treatment, was
held at the Nobel Forum, Karolinska Institutet in
August, 2013 [1]. In May 2015, a national follow-
up conference covering different aspects of biofilm
research was organized in the Birke aula at
Karolinska Institutet, Campus Flemingsberg. The
topics of the meeting included the impact of
biofilm-associated diseases in clinical settings,
the structures of biofilms, biofilm regulation,
development of new tools for biofilm research and
novel anti-biofilm strategies. While biofilm forma-
tion is often described as the natural mode of
microbial growth, it is clear that we still have a lot
to learn about this unique microbial sessile life
style. Much of the microbiological research during
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the last century has focused on the investigation of
the planktonic lifestyle of microorganisms. This
has been without doubt a tremendously successful
endeavour and unravelled basic principles of
metabolism and physiology. The challenge now is
to decipher the specific features of the underre-
searched biofilm lifestyle, because its ubiquitous
nature and its importance in the clinic. Biofilm
communities appear to be more complex than
planktonic cultures. Not only is the cell physiology
different, but any biofilm is composed of cells with
diverse physiology one extreme being represented
by dormant, metabolically silent, and persister
cells. Therefore, new experimental tools that have
a much higher resolution than previously antici-
pated and new physiologically relevant models are
necessary to fully understand the high complexity
of biofilms.
Diagnosis of biofilm infections
Observations of microbial biofilm formation by van
Leeuwenhook, Pasteur and other pioneers date
back to the roots of microbiology and infectious
disease research [2]. The impact of a foreign implant
on the infection process was already recognized in
1956 as the presence of a foreignmaterial required a
7.59104 lower dose of Staphylococcus aureus to
cause a subcutaneous infection in humans which
even then did not resolve [3]. This early study
demonstrated major hallmarks of many biofilm
infections: the presence of a foreign body, which
promotes a persistent infection with a low level of
inflammation that subsequently leads to tissue
destruction. Such were hard to resolve necrotizing
soft tissue infections caused by group A Streptococ-
cus pyogenes, usually a rapidly progressing acute
infection, recently observed to be associated with
in situ biofilm formation, accompanied by a higher
bacterial load and an elevated immune response [4].
The 1956 study also already pointed out biofilm-
associated infections to be characterized by spa-
tially restricted microbial persistence, which
causes a localized immune response. The basic
concept of deleterious biofilms as microbial colo-
nization of the ‘wrong type of bacteria at the wrong
place’, can be even more dramatically exemplified
in the arising association between biofilms and the
development of certain cancers. Recently gathered
evidence indicates the unusual tumour anaplastic
large cell lymphoma, associated with breast
implants, to be connected with a Ralstonia domi-
nated microbiome on the implants [5]. Head and
neck cancer is associated with hygiene-dependent
alterations in oral biofilm formation, exaggerated
by risk factors such as smoking and alcohol
consumption, which negatively affect health-asso-
ciated biofilm properties and thus contribute to the
etiology of tumours [6]. Furtheron, co-colonization
by two toxin-producing bacteria promotes early
onset of polyp formation in individuals with famil-
ial predisposition for adenomatous polyposis [7].
Thus, challenges in the diagnosis of ‘under radar’
infections caused by biofilms include not only the
choice of sample and the sampling procedure,
identification of the organism, and, eventually,
visualization of the usually small biofilm foci [8],
but are to be extended to the microbial composition
in biofilms [5–7]. The European Society for Clinical
Microbiology and Infectious Diseases has compiled
guidelines to reliably diagnose some of the major
biofilm infections as well as has identified research
needs to improve diagnosis, treatment and preven-
tion of biofilm infections [8].
Treatment strategies for biofilm infections
Although some antibiotics such as rifampicin for
Gram-positive bacteria and fluoroquinolones for
Gram-negative bacteria, show a superior ability to
counteract biofilms [6], a total eradication of a
biofilm infection is still a treatment challenge. For
example, an established Pseudomonas aeruginosa
lung infection in cystic fibrosis patients cannot be
eradicated, even following intensive year-long local
and systemic antibiotic therapy. Thus, during a
20 year long infection, daily inhalation of tobramy-
cin/colistin and regular 2-week antimicrobial ther-
apy results in the consumption of 1 kg tobramycin,
1 kg colistin and 10 kg of beta-lactam antibiotic [9],
without effective eradication of the biofilm-forming
pathogens. A consensus agreement exists that only
a combination therapy can potentially eliminate
biofilm infections [9, 10]. Thereby, treatment with
the last resort polymyxin antibiotic colistin is more
effective compared to many other antibiotics under
anaerobic conditions [11]. In vitro treatment of
biofilms, though, induces the formation of a
subpopulation of colistin-tolerant cells that can
subsequently be killed combining colistin with
erythromycin, ciprofloxacin or tetracycline [12–14].
On the other hand, when revisited, widely used
natural antimicrobial compounds demonstrated a
broad efficacy against biofilm-forming microorgan-
isms ([14–17]; Table 1). For example, the
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established antimicrobial preservative acetic acid
is highly effective in the treatment of chronic
wounds infected with biofilm-forming P. aerugi-
nosa [18]. The application of acetic acid might be
extended to combination treatment of other bio-
film-associated diseases including prosthetic joint
infection [18]. Another strategy exploits the anti-
biofilm and immunomodulatory properties of nat-
urally occurring antimicrobial peptides to develop
effective anti-biofilm agents with or without anti-
inflammatory properties in combination with
established antibiotic treatment [19, 20]. The
mechanical dispersion of a mature biofilm can
already significantly enhance antimicrobial
Table 1 Anti-biofilm approaches discussed in the text
Anti-biofilm
approach Optimization Anti-biofilm effect Potential application References
Antimicrobial
surface
material
State-of-the-art machine
learning
Avoidance of cell attachment and
biofilm formation on artificial
surfaces
Artificial devices such
as urinary catheters,
pacemakers, cochlear
implants
[68]
DNases,
proteases,
glycosidase
Enzyme cocktail adapted
to the extracellular matrix
components specific to
the biofilm
Dispersion of the biofilm by
destruction of the extracellular
matrix in combination with
antimicrobials
Skin and wound
biofilm, cystic fibrosis
lung infection
[20]
Application of
antimicrobial
peptides
Enhancement of the
antibiofilm effect while
diminishing the pro-
inflammatory effect
Dispersion of established biofilms
and avoidance of biofilm formation
on artificial surfaces
Artificial devices such
as urinary catheters
[19, 20]
Photodynamic
therapy
Use of high energy blue
antimicrobial light
Targeting of photoreactive
compounds to create reactive
oxygen and nitrogen species
Skin biofilm, wound
infection
[27]
Atmospheric
cold plasma
Production of reactive
oxygen and nitrogen
species
Reactive oxygen and nitrogen species
target lipids, proteins and other
macromolecules
Wound infection [28]
Low frequency
ultrasonic
therapy
To optimize amplitude,
frequency, contact time,
instrument configuration
Physical intervention to disperse the
biofilm with mechanical energy to
reach an anti-microbial effect in
combination with chemical therapy
Wound infection,
periprosthetic joint
infection
[29–31]
Acetic acid Combination treatment Traditional effective antimicrobial, in
use to treat infections like
Swimmer’s ear and chronic wounds
Other types of biofilm
infections like
prosthetic joint
infection
[18]
Nitric oxide,
NO
Dose-dependent
antimicrobial and
antibiofilm effect
Innate immune and signalling
molecule that is sensed by sensory
protein domains to subsequently
induce biofilm dispersion in a broad
range of bacteria
Inhalation to treat
cystic fibrosis lung
infection caused by
P. aeruginosa
[16, 100]
Hypochlorous
acid, HOCl
Innate antimicrobial agent
in combination with
physical interventions
Peroxidase-generated anti-bacterial
innate immune molecule
Wound infection [17, 101]
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susceptibility. Therefore, the efficiency of antibiotic
treatment can be increased by a combination
therapy with biofilm matrix degrading enzymes
such as DNases, proteases and glycoside hydro-
lases ([20, 21]; Table 1). The applicability of anti-
matrix and sequestration molecules has been
recently reviewed [20].
A major hurdle for a rationalized strategy for
dispersal by biofilm matrix hydrolysis is the lack
of a detailed understanding of the composition of
the extracellular matrix (ECM) and the arrange-
ment of macromolecules in clinically relevant
biofilms. Small molecules can aid in the charac-
terization of the composition and arrangement of
the ECM. Those molecules can either interact
selectively with common components of the ECM
of biofilms or bind to different unrelated matrix
molecules to cause specific spectral shifts. Estab-
lished compounds that have been used to charac-
terize the ECM of biofilms are, for example,
thioflavin T, which binds to amyloid fibers and
Calcofluor white (fluorescence brightener 28),
which binds to 1?3 and 1?4 b-glucans such as
the exopolysaccharide cellulose. On the other
hand, Congo red can bind to both, exopolysaccha-
rides and amyloid fibers [22–25]. In the search for
alternative compounds, luminescent conjugated
oligothiophene derivatives were recently identified
through compound library screening approaches
to selectively interact with curli amyloid fibres and
cellulose, respectively [26]. If successfully broad-
ened, this approach could aid the in-depth char-
acterization of biofilm formation in vitro and
in vivo.
Several biophysical approaches for the treatment of
biofilm infections have been implemented. One of
them involves photodynamic therapy, the applica-
tion of light, in particular blue light, to activate
photosensitive compounds such as (proto)por-
phyrins, ubiquitously present in bacterial organ-
isms (Table 1). The FDA approved therapeutic blue
light has ahigh energy and is effectively absorbed by
photosensitivemolecules.As such,blue light causes
a substantial decrease in cell viability in clinically
significant biofilms in vitro and in vivo due to the
powerful cytotoxic effect based on electron transfer
leading to the creation of reactive oxygen species
[27]. Chemically reactive species are also effective as
anti-biofilm agents in the external application of
atmospheric cold plasma against biofilms ([28];
Table 1). Low frequency ultrasonic therapy, clini-
cally applied to improve chronic wounds, has been
shown effective against biofilm-forming microor-
ganisms in experimental infections, probably
through the generation of mechanical forces [29–
31]. It is worth noting, though, that any successful
antimicrobial therapy needs to be supported by a
functional immune system to eradicate the foci of
infection. Indeed, the future challenge is not only to
develop successful strategies to eradicate biofilm
infections by antimicrobial therapy, but also to aid a
self-healing immune response that is compromised
in many patients (see below; [32]).
Prevalent biofilm infections
Skin and subcutaneous infections, including burn
wounds, surgical-site infections and nonhealing
pressure, venous, arterial and diabetic ulcers are
common health problems in industrialized and
developing countries that pose a significant eco-
nomical burden for the society. Chronically
infected diabetic foot ulcer, often associated with
polymicrobial biofilm formation, is considered the
most significant wound care problem in the world
affecting up to 25% of diabetic individuals at least
once in their lifetime [33]. As diabetes is increasing
especially in developing countries [34], the problem
of diabetic foot infection with a potential risk for
amputation is rapidly growing, with challenges in
diagnosis and treatment [35]. Investigation of the
microbial wound ecology has revealed that host
factors substantially modulate the infection pro-
gress promoting a unique biofilm ecology. Under
laboratory conditions, P. aeruginosa can kill S. au-
reus in mixed culture. In the wound, however,
albumin at physiological levels promotes co-colo-
nization of these two most prevalent wound patho-
gens preventing killing of S. aureus by
P. aeruginosa (Fig. 1a; [36, 37]). Further on,
P. aeruginosa and S. aureus co-colonization
enhances tolerance to some antibiotics [37]. On
the other hand, insulin treatment, which has
known immunomodulatory effects, enhances
P. aeruginosa biofilm formation and antibiotic tol-
erance [38]. In addition to chronic wounds, dia-
betes patients have been observed to harbour
bacterial biofilms in arterial artherosclerotic pla-
ques, which are considered to be a major factor
compromising circulation and negatively affecting
disease progression [38]. Initial characterization of
the physiology of the major wound pathogen
P. aeruginosa by transcriptome profiling and gen-
ome-wide mutant fitness profiling by Tn-seq
revealed in vivo metabolic requirements such as
long chain fatty acids as a major carbon source. In
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these studies, chemotactic flagellar motility was
identified as a major contributor to virulence in
acute, but not in chronic wound infections [39].
The oral biofilm is one of themost complexmicrobial
community in the human body. Over 700 species
have been estimated to contribute to dental plaque
biofilm formation, which have been classified into
‘so-called’ colour-coded complexes on the basis of
sequential colonization in combination with their
impact on oral health [40]. Oral diseases such as
dental caries, gingivitis, periodontitis and peri-
implantitis are among the most common biofilm
diseases [41, 42]. Periodontitis, a chronic, tissue-
destructive inflammation, which degrades the
attachment apparatus of the teeth, can cause tooth
loss and, in its most severe form, edentulousness,
the complete loss of all natural teeth. Microbial
plaque (biofilm) forms on hard and soft tissues, first
supragingivally then subgingivally with mainly the
bacterial pathogens of the orange and red complex
that strongly associate with periodontitis such as
Aggregatibacter actinomycetemcomitans, Porphy-
romonas gingivalis and Treponema denticola as
etiological agents [43]. This subgingival biofilm
formation, which brings a massive bacterial load
(a)
(b) (c)
Fig. 1 (a) P. aeruginosa (red) and S. aureus (green) grown together in a ‘wound-like’ media that supports their co-culture as
patchy distinct microcolonies. A three-dimension segment of the medium is shown from different angles. Image by Cody Fell
(Rumbaugh laboratory), unpublished. (b) Visualization of P. aeruginosa biofilms in a CF lung of a CF male, 41 years of age,
chronic P. aeruginosa mucoid and nonmucoid infection for 28 years, 46 precipitating antibodies, 114 2-week anti-
P. aeruginosa treatment courses. Intraluminal P. aeruginosa biofilms surrounded by polymorphonuclear leukocytes (PMNs)
visualized using peptide nucleic acid – fluorescence in situ hybridization (PNA-FISH) and DNA staining with 40,
6-Diamidin-2-phenylindol, (DAPI). Adapted from [9]. (c) P. aeruginosa grown in artificial sputum medium. Adapted from [95]
with permission.
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close to the blood vessels, in combination with
inflammation and inflammatory mediators in the
periodontium, is associated with a range of chronic
diseases [44, 45]. As such, oral health does not only
have an impact on the oral cavity, but can be
involved in the etiology of various diseases such as
cardiovascular diseases e.g. endocarditis and
stroke and systemic inflammatory diseases such
as rheumatoid arthritis [46, 47].
Elucidation of the molecular basis of biofilm formation
Major regulatory circuits controlling biofilm forma-
tion have been unravelled and a range of biofilm-
associated extracellular matrix (ECM) components
discovered in well-established in vitro and in vivo
models (Fig. 1b, c; [48, 49]). ECM components
such as exopolysaccharides, proteinaceous pili/
fimbriae, other protein components, nucleic acids
and lipids are most often stabilized through inter-
molecular networks involving specific binding pro-
teins or networking between ECM components [22,
50, 51].
The impact of extracellular DNA (eDNA) for the
integrity of biofilm structures was discovered as
DNase treatment dissolved early and established
biofilms [52, 53]. Thereby, choline-binding pro-
teins can act as positively charged bridges between
eDNA and the cell surface and so can cytoplasmic
proteins, released and surface exposed in a ‘moon-
lighting’, second independent, function [54, 55].
The surface-associated Pneumococcal Serine Rich
repeat Protein PsrP, a member of the serine rich
repeat protein (SRRP) family, exemplifies one
eDNA-receptor that promotes cell clumping and
biofilm formation (Fig. 2a). While the C-terminal
serine rich-repeat (SRR) region is anchored in the
capsular surface, the unique functional binding
region (BR) domain mediates adherence to lung
associated keratin 10 and promotes biofilm forma-
tion [56, 57]. The crystal structure of the BR
domain of PsrP revealed a novel variant of the
DEv-IgG fold, typical for microbial surface compo-
nents recognizing adhesive matrix molecule
(MSCRAMM) adhesins [58]. The BR domain weakly
associates into a b-sheet dimer resembling a
molecular saddle with a highly basic concave
under-surface that snuggly fits the acidic helical
structures of eDNA or keratin 10 [58]. However,
molecular structures of BR in complex with its
ligands are required to confirm the suggested
binding models.
A common ECM component of enterobacterial
biofilms is the exopolysaccharide cellulose [59].
Thereby, the cellulose biosynthesis operon is pre-
sent not only in environmental species, but also in
human pathogens [60]. Cyclic di-GMP signalling
(see below) was identified as a major post-transla-
tional regulatory mechanism leading to the activa-
tion of cellulose biosynthesis [60]. BcsZ, a cellulase
of glycoside hydrolase (GH) family 8 is associated
with cellulose biosynthesis operons, however, its
function remains controversial. In the gastroin-
testinal pathogen Salmonella enterica serovar
Typhimurium, in accordance with its enzymatic
functionality, BcsZ negatively regulates cellulose
biosynthesis [61]. Thereby, the periplasmic protein
inversely regulates the major bacterial life styles
biofilm formation and motility. Strikingly, although
regulation of cellulose biosynthesis was not obvi-
ous under laboratory conditions at body tempera-
ture, bcsZ was required for efficient establishment
of an infection in the mouse model of typhoid fever.
Key virulence phenotypes of S. Typhimurium such
as organ colonization and uptake and proliferation
in macrophages were positively regulated by bcsZ.
Most of the phenotypes mediated by bcsZ were
relieved upon deletion of the cellulose synthase
BcsA and/or the major biofilm activator CsgD,
which indirectly regulates cellulose expression
through activation of the diguanylate cyclase AdrA
(Fig. 2b). Thus bcsZ effectively downregulates csgD
mediated cellulose biosynthesis to enable Sal-
monella to efficiently cause acute infection [61].
Consequently, the BcsZ cellulase is the example of
a periplasmic enzyme involved in the adjustment of
biofilm formation versus motility and virulence
downstream of major cytoplasmic biofilm hubs
such as the cyclic di-GMP signaling system. Such a
multilayer regulation might also occur in other
bacteria, which produce cellulose as an extracel-
lular matrix component of biofilms.
Elucidation of biofilm properties
Epithelial surfaces in the human body are very
efficient in keeping microorganisms under surveil-
lance. Artificial medical devices, however, which
are obviously devoid of major innate immune
defense mechanisms, become readily colonized by
microbes. A prominent example is urinary tract
catheters, which have a colonization probability of
5–10% per day. Experts working in networks such
as “ipromedai”, “improved protection of medical
devices against infection” (www.ipromedai.net), are
developing novel antimicrobial and biocompatible
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surfaces. Biofilm formation on surfaces is multi-
factorial, influenced by the particular strain, the
growth medium and, last but not least, surface
characteristics. As such, the capability to form a
biofilm, biofilm ECM components and the regula-
tory biofilm network can vary substantially
PsrP
eDNA
KRT10/KRT1
Airway surface
BR domain
c-di-GMPc-di-GMP
BcsA
BcsA
PilZ
PilZ
AdrA
AdrA
CsgD
BcsE
BcsZ
BcsE
surface
IM
OM
Periplasm
Cellulose microfibril
BcsZ
(a)
(b)
Fig. 2 Novel molecular mechanisms involved in regulation of biofilm formation. (a) The giant protein PsrP of Streptococcus
pneumoniae promotes colonization in the airways through multiple binding events. PsrP, via its BR domain located outside
of the capsule, binds to biofilm-associated eDNA and adheres to surface accessible keratin (KRT) 10/KRT 1 as well as self-
associates via BR domains. (b) The cellulase BcsZ located in the periplasm regulates cellulose production independently of
cyclic di-GMP in S. typhimurium. Cyclic di-GMP (c-di-GMP) regulates expression of csgD encoding the major biofilm regulator.
Subsequently, csgD activates transcription of the diguanylate cyclase AdrA to synthesize the cyclic di-GMP involved in
production of the exopolysaccharide cellulose via binding to the cyclic di-GMP receptors BcsE and a PilZ domain at the C-
terminal end of the cellulose synthase BcsA.
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between clinical isolates of the same species [62].
This biological variability has to be addressed in
the development of anti-biofilm strategies. For
example, the biofilm formed by Pseudomonas
aeruginosa on a catheter surface in artificial urine
is composed of a specific type of extracellular
matrix partially dependent on eDNA [63]. This
contrasts biofilm formation under alternative
growth conditions where alginate, PEL and PSL
exopolysaccharides are major extracellular matrix
components. Remarkably, though, the second
messenger cyclic di-GMP (see below) directs biofilm
formation even under these substantially different
environmental conditions [64] making this mole-
cule a general anti-biofilm target. Surface charac-
teristics that determine attachment and
subsequent biofilm formation are hydrophobicity
and surface charge; two parameters modulated, for
example, by the application of polymer brushes.
Thereby, a polycationic surface can dramatically
enhance, while an anionic and zwitterionic surface
can dramatically decrease biofilm formation,
although leaving dense macrocolonies, roughly
concomitant with the surface contact angle [65].
Furthermore, irregularities on a surface and sur-
face patterning can affect biofilm formation [66].
Unconventional inclusion of anti-microbial sub-
stances in innovative surfaces also reduces bacte-
rial adhesion [67]. Recently developed machine
learning approaches might accelerate the design of
effective antimicrobial surfaces [68].
It has to be pointed out, though, that a successful
microbe-free implantation is not only determined
by the implant surface characteristics, but also by
the health status of the patient and disease
parameters. For example, smoking, severe obesity
and diabetes are well-known risk factors for post-
operative infections, which automatically lead to
an increase in the foreign body infection rate [69–
71]. As such, the rate of infection can vary dra-
matically from 0.75% to 35% depending on implant
characteristics and the patients’ health status.
Better understanding of biofilm properties requires
advanced imaging technologies. The resolution of
light microscopy is limited by the wavelength of
light. The development of different live-cell nano-
scopy techniques such as stimulated-emission
depletion (STED) microscopy has overcome these
physical constraints and thus has revolutionized
the exploration of living cells at molecular resolu-
tion [72, 73]. In microbiology, nanoscopy has been
applied, for example, to investigate the nucleoid
structure and associated machineries [74].
Another technical development, atomic force
microscopy (AFM), has facilitated new opportuni-
ties for imaging and manipulation of biological
systems at the level of single cells and molecules
[74, 75]. Originally developed for the scanning of
technical surfaces, in force production between the
tip and the surface enables AFM to unravel the
surface architecture of single live cells at nanoscale
in real time. The self-assembly of S-layer proteins
and the effect of antimicrobial substances on cell
walls has been observed with AFM [76]. AFM has
also been used to investigate physical properties of
biofilm communities such as an inverse correlation
between the elasticity and cellulose production of
an Aliivibrio fischeri biofilm [77]. Beyond imaging,
AFM has been developed to probe forces in single-
molecule spectroscopy to understand processes
such as adhesion, unfolding and sugar recognition.
Single-cell force spectroscopy is also used to assess
mechanisms of cell adhesion. These analyses
complement traditional methods to analyse the
gene-function relationship of microbial cells at the
nanoscale and structure-function relationships in
the biological context [74].
Translational applications – from biofilms to treatment
Although first described as an allosteric regulator
of the cellulose synthase, the bacterial cyclic di-
nucleotide second messenger cyclic di-GMP was
early on suspected to be involved in interkingdom
crosstalk [78, 79]. These first studies described
effects of cyclic di-GMP on the retardation of
growth of cancer cell and preliminary identified
eukaryotic receptors. A number of follow-up stud-
ies have demonstrated that cyclic di-GMP and
subsequently identified bacterial cyclic di-nucleo-
tide second messengers indeed cause broad phys-
iological responses, including the activation of a
multifactorial innate and adaptive immune
response [80, 81]. Furthermore, experimental data
indicate that cyclic di-GMP and its nonhydrolizable
analogues can efficiently induce shrinkage of
tumours [82]. However, what are the molecular
mechanisms by which cyclic di-GMP and other
bacterial cyclic di-nucleotide second messengers
cause such a broad response?
The most prominent cyclic di-GMP receptor is the
immune adaptor STING that binds cyclic di-GMP
with a dissociation constant of 5 lM and triggers a
downstream signalling cascade with relocalization
of STING to stimulate type 1 interferon production
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[83]. Indeed STING also binds the bacterial second
messengers cyclic di-AMP and the cyclic 30-30
GAMP hybrid, but the physiological substrate is
the intrinsic innate immune second messenger
cyclic 20-30-GAMP [84]. Subsequent identification
of additional human cyclic di-GMP receptors
(Table 2) starts to explain the multi-faceted effects
of cyclic di-nucleotide signalling that extend
beyond the activation of the immune system and
aid unravelling an intricate crosstalk between
microbial and metazoan signalling systems.
In an unexpected twist of events, the hyperpolar-
ization-activated cyclic nucleotide gated (HCN) ion
channel 4 was identified as a cyclic di-GMP
responsive protein. HCN4 ion channels are the
molecular determinants of the cardiac pacemaker
current responsible for the automaticity of the
heart [85]. In the physiological setting, the auto-
nomic regulation of the heart rate is affected by
direct binding of cAMP to HCN channels, which
increases channel current. Binding of cAMP to the
cyclic nucleotide-binding domain (CNBD) of HCN
channels subsequently promotes a conformational
change that is transmitted via the C-linker to the
pore and enhances the probability of channel
opening. Unexpectedly, the C-linker contains a
binding pocket for the bacterial and mammalian
Table 2 Mammalian cyclic di-GMP receptors and their features
Receptor Specificity Affinity Function C-dinucleotide effect References
STimulator of
INterferon Genes,
STING
c-di-GMP,
c-di-AMP,
3030-cGAMP,
2030-cGAMP
Kd = 5 lM (c-di-GMP)
to C-terminal
domain; 1:2
stoichiometry;
Kd = 61 nM (2030-
cGAMP)
Innate immune
adaptor
type 1 IFN
stimulation; some
STING alleles have
lost binding capacity
[102]
Helicase DDX41 c-di-GMP;
c-di-AMP
Kd = 5.7 lM
(c-di-GMP)
Interacts with STING;
STING activation
type 1 IFN
stimulation
[103]
Hyperpolarization-
activated cyclic
nucleotide-gated
channel 4 (HCN4)
c-di-GMP,
c-di-AMP,
2030 and
3030- cGAMP
Ka = 1.8 lM
(c-di-GMP)
Nonselective ligand-
gated cation
channel in heart and
brain
Counteracts cAMP
dependent HCN
channel open
probability, reduces
heart rate
[86]
A2a adenosine
receptor
c-di-AMP,
3030-cGAMP
IC50 = 2.5 lM
(c-di-AMP)
Monocyte Gas-
coupled adenosine
receptor
Apoptosis [86]
Human
siderocalin
LCN2
c-di-GMP Kd = 1.63 lM Siderophore receptor Competition with
ferric siderophores,
antagonizes
antibacterial activity
[104]
RECON c-di-AMP,
3030-cGAMP
Kd = 87 nM
(c-di-AMP)
Oxidoreductase;
aldo-keto reductase
family 1; member
C13 (AKR1C13)
Inhibition of
enzymatic activity;
NF-jB activation;
reduced bacterial
survival
[105]
ERAdP c-di-AMP Kd = 76 nM Endoplasmatic
reticulum
membrane adaptor
Promotes pro-
inflammatory
cytokine production
through NF- jB
[106]
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cyclic dinucleotides [86] that prevent cAMP modu-
lation of the current in HCN4 and leads to heart
rate reduction in mouse myocytes by about 30%.
These and other findings indicate that cyclic
di-GMP and other microbial derived cyclic (di)
nucleotides can have a much wider impact on
human physiology than what has been previously
appreciated. It is therefore possible that these kind
of second messenger molecules can have a
therapeutic potential comparable to small chain
fatty acids produced abundantly by the gut micro-
biome [87].
In its genuine context, the bacterial second mes-
senger cyclic di-GMP plays a determinative role in
motile-to-sessile and acute-to-chronic virulence
lifestyle transitions in many, if not most bacteria.
As the exposure to a regular light-dark cycle is a
PAS GAF PHY GGDEF
GTPc-di-GMP
c-di-GMP pGpG
Biliverdin
EAL BLUF
FAD
(a)
(b)
UVA IR
400 nm200 nm 300 nm 500 nm 600 nm 700 nm
>750 nm
Visible light
LOV
Xanthopsin
Phytochrome
BLUF
UVBUVC
Wave length
Fig. 3 Light directed control of bacterial behavior. (a) Absorption range of characterized photoreceptor domains that are
coupled to downstream bacterial cyclic dinucleotide signalling domains [88]. Chromophores such as biliverdine/bilin
derivatives, flavin derivatives such as FAD or cumarin that sense light of different wave length are covalently or
noncovalently coupled to the protein scaffold of photoreceptors in phytochromes (including bacteriophytochromes and
cyanobacteriochromes), LOV/BLUF and xanthopsin proteins, respectively [96–98]. Phytochrome/phytochrome-like proteins
contain PAS/GAF/PHY domains in various combinations [99]. (b) Engineering of an optogenetic system to regulate cyclic di-
GMP levels bidirectionally. A red light-activated diguanylate cyclase (based on a bacteriophytochrome photoreceptor with a
biliverdine chromophore) and a blue light-activated phosphodiesterase (based on a BLUF domain photoreceptor with an FAD
chromophore) to regulate motility (left) and Congo red stained biofilm formation (right) [92].
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major determinant of life, it is not surprising that
these life style transitions can be controlled by
photoreceptor signalling domains covering the vis-
ible spectrum of light (Fig. 3; [88]). Thereby, pho-
toreceptors that belong to several different classes
such as the BLUF, the LOV or bacteriophytochrome
domain are coupled to diguanylate cyclases and
cyclic di-GMP phosphodiesterases in different bac-
terial phyla. Not surprisingly, many of the light-
activated enzymes are found in phototrophic bac-
teria, including cyanobacteria [89]. Superior tem-
poral and spatial restriction compared to chemical
inducers suggests light as an attractive stimulus to
manipulate bacterial and eukaryotic physiology by
cyclic (di)nucleotide second messenger signalling
through tailor-suited engineering of signal trans-
duction pathways [90]. Proof-of-principle, first
exemplified by an algal photoactivated adenylate
cyclase [91], stimulated the subsequent develop-
ment of synthetic light-regulatedmodules to control
cyclic di-GMP levels in bacterial as well as animal
cells. In bacteria, the combination of synthetic
modules can be used to differentially manipulate
intrinsic bacterial behaviour such as motility,
biofilm formation and virulence with light of differ-
ent wavelengths in in vitro and in vivo studies
(Fig. 3b; [92]). In bacterial and animal cells that
lack cyclic di-GMP signalling pathways, light-acti-
vated cyclic di-nucleotide modules can be linked to
downstream effector modules for orthogonal regu-
lation of biological processes through manipulation
of e.g. gene expression, protein activities or protein–
protein interactions [93]. Although the broad spec-
trum of light can be used for various therapeutic
purposes, nondestructive low-energy near-infrared
light penetrates most deeply into mammalian tis-
sue. Photocontrol of cyclic (di)nucleotide-based
modules can thus be used in the temporal and
spatial precision manipulation in host-bacterial
interactions in mammalian models with the aim to
develop innovative therapeutics. These secondmes-
senger based modules can also be adapted for
remote control of stem, immune or other mam-
malian cells with an intrinsic and/or engineered
response, which eventually will lead to the develop-
ment of novel treatment options [94].
Conclusions
Biofilm-associated infections still remain a diag-
nostic and treatment challenge. However, besides
the initiation of pipelines to discover novel anti-
biofilm compounds, even traditional antimicrobial
compounds can provide a significant anti-biofilm
effect and are (re)discovered for extended clinical
use also in combination with physical and chem-
ical treatment strategies. In-depth analyses of the
ECM components of biofilms will provide the
molecular basis to develop efficient cocktails of
ECM degrading enzymes as powerful biofilm dis-
persal agents tailor-suited for a respective clinical
biofilm. It is the combination of novel anti-biofilm
strategies with traditional antibiotics that pro-
mises to master the challenge of eradication of
biofilm infections. The regulatory molecules
known to play key roles in biofilm regulation such
as the second messenger cyclic di-GMP and
related cyclic (di)nucleotide second messengers
are targets for anti-biofilm strategies. Extending
their regulatory context, light sensing domains
coupled to cyclic (di)nucleotide turnover domains
can be developed as signal-input amplifying mod-
ules to construct remote-controlled interkingdom
cross-talk modules to be applied for innovative
treatment options.
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